Skip to content
DraconiticResearch
Search Sources API
182,549 studies31 sourcesUpdated 27 min ago
Peer-reviewedCC BY-NC-NDBMC microbiology

In vitro and in vivo antibacterial activity of pravibismane against Mycobacteroides abscessus.

  • Amy Leestemaker-Palmer1
  • Bailey Keefe1
  • Luiz E Bermudez2,3
  • Brett H J Baker4
4 affiliations
  1. 1Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Corvallis, OR- 97331, USA.
  2. 2Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Corvallis, OR- 97331, USA. [email protected].
  3. 3Department of Microbiology, College of Sciences, Oregon State University, Corvallis, OR- 97331, USA. [email protected].
  4. 4Microbion Corporation, Bozeman, MT- 59715, USA. [email protected].
Read full textPDFDOICite

Abstract

The increasing prevalence of non-tuberculous mycobacterial lung infection represents a global challenge. Infections caused by Mycobacteroides abscessus commonly occur in individuals with underlying predisposing lung diseases such as cystic fibrosis (CF), non-CF-bronchiectasis, chronic obstructive pulmonary disease (COPD), and tuberculosis (TB). The unmet need in the treatment of M. abscessus pulmonary infection is driven by multidrug-resistance, ability to form biofilms, lengthy treatment, and drug-related side effects. Pravibismane was evaluated for its potential to reduce M. abscessus burden in vitro and in vivo. Pravibismane exhibited significantly lower (16- to 32-fold) minimum inhibitory concentrations (MICs) compared to amikacin. Treatment of THP-1 M. abscessus-infected macrophages with pravibismane led to a rapid reduction in intracellular M. abscessus while maintaining the viability of the THP-1 macrophages. Pravibismane demonstrated to be well-tolerated and efficacious in a chronic mouse M. abscessus lung infection model in which 28-day treatment with inhaled pravibismane substantially reduced the burden of M. abscessus in murine lung tissues. Overall, pravibismane exhibited promising efficacy by reducing intracellular M. abscessus levels in vitro and in a chronic mouse infection model. These preclinical results warrant investigation of pravibismane's ability to treat M. abscessus lung infection in relevant patient populations.

Related

  1. Modifications to a vegan artificial honey result in inhibitory activity against Mycobacterium abscessus
    Victoria C. Nolan, James Harrison, Jonathan A. G. Cox
    PLOS OnePeer-reviewedCC BY 4.0Full textMicrobiologyZoology & animal behaviourPLOS
  2. Antibacterial Activity of Equisetin from Endophytic Fusarium incarnatum JMB4 Associated with Jatropha multifida L. Against MRSA: Experimental and In Silico Insights
    Herland Satriawan, Rachel Shammara Khalda, Hao-Ze Li +3
    ACS OmegaPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMC
  3. Genome mining, antibacterial activity, and metabolomic profiling reveal the biosynthetic potential of Burkholderia glumae isolates from Thailand with activity against clinically important bacterial pathogens
    Sujin Patarapuwadol, Panalee Oupaijit, Pornpavee Nualnisachol +2
    PLOS OnePeer-reviewedCC BYFull textEnzymology & metabolismProteomics & metabolomicsPLOSEurope PMCPMC
  4. Determinants of Antibacterial Activity in Humulus lupulus Hop Extracts: Phytochemical Profiling of Prenylated Acylphloroglucinols and Efficacy Against Methicillin-Resistant Staphylococcus aureus and Multidrug-Resistant Uropathogenic Escherichia coli
    Przemysław Leszczyński, Dorota Wojnicz, Dorota Tichaczek-Goska +3
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  5. Plant-part specific in vitro antibacterial activity of crude ethanolic extracts of Mangifera indica against Salmonella typhi: an exploratory study.
    Ivan Ronald Omara, Juliet Kyayesimira, Stephen Charles Olet
    BMC complementary medicine and therapiesPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{leestemakerpalmer2026vitro,
  title = {{In vitro and in vivo antibacterial activity of pravibismane against Mycobacteroides abscessus.}},
  author = {Amy Leestemaker-Palmer and Bailey Keefe and Luiz E Bermudez and Brett H J Baker},
  journal = {BMC microbiology},
  year = {2026},
  month = jul,
  doi = {10.1186/s12866-026-05446-1},
  url = {https://europepmc.org/article/MED/42902132},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - In vitro and in vivo antibacterial activity of pravibismane against Mycobacteroides abscessus.
AU  - Amy Leestemaker-Palmer
AU  - Bailey Keefe
AU  - Luiz E Bermudez
AU  - Brett H J Baker
PY  - 2026
DA  - 2026/07/01
JO  - BMC microbiology
DO  - 10.1186/s12866-026-05446-1
UR  - https://europepmc.org/article/MED/42902132
AB  - The increasing prevalence of non-tuberculous mycobacterial lung infection represents a global challenge. Infections caused by Mycobacteroides abscessus commonly occur in individuals with underlying predisposing lung diseases such as cystic fibrosis (CF), non-CF-bronchiectasis, chronic obstructive pulmonary disease (COPD), and tuberculosis (TB). The unmet need in the treatment of M. abscessus pulmonary infection is driven by multidrug-resistance, ability to form biofilms, lengthy treatment, and drug-related side effects. Pravibismane was evaluated for its potential to reduce M. abscessus burden in vitro and in vivo. Pravibismane exhibited significantly lower (16- to 32-fold) minimum inhibitory concentrations (MICs) compared to amikacin. Treatment of THP-1 M. abscessus-infected macrophages with pravibismane led to a rapid reduction in intracellular M. abscessus while maintaining the viability of the THP-1 macrophages. Pravibismane demonstrated to be well-tolerated and efficacious in a chronic mouse M. abscessus lung infection model in which 28-day treatment with inhaled pravibismane substantially reduced the burden of M. abscessus in murine lung tissues. Overall, pravibismane exhibited promising efficacy by reducing intracellular M. abscessus levels in vitro and in a chronic mouse infection model. These preclinical results warrant investigation of pravibismane's ability to treat M. abscessus lung infection in relevant patient populations.
SN  - 1471-2180
ER  -